
|Videos|October 1, 2015
Can Biosimilars Reduce Specialty Spending?
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement














































































































































































































